Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-22T07:06:04.012Z Has data issue: false hasContentIssue false

Substantial Amendment of the EU Regulatory Framework on Medical Devices and International Trade Implications

Published online by Cambridge University Press:  20 January 2017

Ignacio Carreño*
Affiliation:
FratiniVergano, Brussels

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Reports
Copyright
Copyright © Cambridge University Press 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 COM(2012) 542.

2 COM(2012) 541.

3 There is reportedly an increasing trend in EU medicines agencies of “medical device” applications for food supplement products which have been rejected under the strict EU health claims framework, set out in Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods, OJ 2006 L 404/9). See: Shane Starling, “EU medical devices route tempts article 13 health claim losers”, 3 January 2013, available on the Internet at: <http://www.nutraingredients.com/Regulation/EU-medical-devices-route-temptsarticle-13-health-claim-losers> (last accessed on 3 January 2013).

4 OJ 1990 L 189/17.

5 OJ 1993 L 169/1.

6 OJ 1998 L 331/1.

7 COM(2012) 540 final.

8 OJ 2011 C 202/7.

9 European Parliament Document P7_TA(2012)0262.

10 See on the Internet at: <http://www.ghtf.org> (last accessed on 3 January 2013).

11 See on the Internet at: <http://www.imdrf.org> (last accessed on 3 January 2013).

12 WTO Doc. G/TBT/N/EU/71 and WTO Doc. G/TBT/N/EU/72.

13 WTO Doc. G/TBT/N/BRA/440.

14 OJ 2002 L 31/1.

15 OJ 2003 L 268/24.

16 OJ 2004 L 10/5.